CM313 for Pemphigus: A single-center study
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new drug, CM313, for people with moderate to severe pemphigus (a blistering skin disease). It aims to see if the drug can help heal the blisters and sores.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with pemphigus (a rare autoimmune disease that causes blisters on skin and inside the mouth).
- Your pemphigus is moderate to severe, meaning your doctor has measured your blisters and sores with a special score (PDAI) of 9 or higher.
- You are not pregnant or planning to become pregnant, and you are not breastfeeding.
- You do not have an active infection such as HIV, hepatitis B or C, tuberculosis, or syphilis.
- You have not received certain strong treatments (like IV cyclophosphamide, plasma exchange, or immunoadsorption) in the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called B007 for people with pemphigus, a rare autoimmune disease that causes painful blisters on the skin and inside the mouth. It aims to see if B007 can control the disease and allow patients to reduce other treatments.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
This trial tests a new drug called CM313 for people with moderate to severe pemphigus, a blistering skin condition. It's for patients who haven't had this treatment before and may have not responded well to other therapies.
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
This trial tests a new injection (CM313) to see if it can help people with active lupus. It's for those whose lupus symptoms aren't fully controlled despite standard treatments.
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
Hear when a new Pemphigus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.